Back to top

Analyst Blog

Sanofi’s (SNY - Analyst Report) new drug application (NDA) for its basal insulin candidate, Toujeo, has been accepted for review by the FDA. Toujeo is a new formulation of Lantus (insulin glargine). The FDA is expected to render a final decision on the candidate in the first half of 2015.

The NDA for Toujeo was submitted on the basis of encouraging data from the phase III EDITION studies, which evaluated the efficacy and safety of Toujeo in more than 3,500 patients suffering from diabetes. Toujeo is already under regulatory review in the EU.

Last month, Sanofi released data from a pooled analysis of Toujeo. According to the data, significantly fewer low blood sugar events (hypoglycemia) at any time of the day, including night-time events, were observed in patients receiving Toujeo as compared to Lantus.

Lantus is one of the top-selling drugs at Sanofi. The drug generated sales of €1.4 billion in the first quarter of 2014. However, we note that Eli Lilly and Co. (LLY - Analyst Report) along with partner Boehringer Ingelheim is looking to get their generic version of Lantus approved in the EU. The candidate has already received a positive opinion from the Committee for Medicinal Products for Human Use.

Toujeo on approval is expected to strengthen Sanofi’s product portfolio. In order to boost its diabetes portfolio, Sanofi is also developing LixiLan, a fixed dose combination of Lantus and Sanofi’s Lyxumia (once-daily injectable glucagon-like peptide 1/GLP-1 receptor agonist). In the first quarter of 2014, the company initiated two phase III studies on the candidate.

Although Sanofi holds a strong position in the diabetes market, we note that the market includes players like Novo Nordisk (NVO - Analyst Report) and Eli Lilly.

Sanofi carries a Zacks Rank #3 (Hold). A better-ranked stock in the health care sector, Biogen Idec Inc. (BIIB - Analyst Report), holds a Zacks Rank #1 (Strong Buy).

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
ERBA DIAGNO… ERB 2.99 +2.75%
CTPARTNERS… CTP 16.25 +2.33%
CHINA BIOLO… CBPO 46.93 +1.88%
THE PANTRY… PTRY 20.97 +1.82%
NN INC NNBR 28.43 +1.46%